Pruvanserin

Pruvanserin (EMD 281014 free acid) is a selective 5-HT2A receptor antagonist. Pruvanserin alleviates tactile allodynia in diabetic rats. Pruvanserin can also be used for research of insomnia[1].

Product Specifications

CAS Number

[443144-26-1]

Product Name Alternative

EMD 281014 (free acid) ; LY 2422347

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

5-HT Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/pruvanserin.html

Purity

99.27

Solubility

DMSO : ≥ 100 mg/mL

Smiles

N#CC1=CNC2=C1C=CC=C2C(N3CCN(CC3)CCC4=CC=C(C=C4)F)=O

Molecular Formula

C22H21FN4O

Molecular Weight

376.43

Precautions

H302, H315, H319, H335

References & Citations

[1]Abbas A, et al. Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders. Expert Opin Pharmacother. 2008 Dec;9 (18) :3251-9. |[2]Mixcoatl-Zecuatl T, et al. A spinal mechanism of action for duloxetine in a rat model of painful diabetic neuropathy. Br J Pharmacol. 2011 Sep;164 (1) :159-69.